New drug combo shows promise for Tough-to-Treat blood cancer
NCT ID NCT02159755
First seen Jan 10, 2026 · Last updated May 16, 2026 · Updated 24 times
Summary
This early-phase trial tested a combination of two targeted drugs, ibrutinib and palbociclib, in 28 adults with mantle cell lymphoma that had come back after prior treatment. The main goal was to find the safest dose and see how well the drugs shrink tumors. Both drugs work by blocking signals that help cancer cells grow.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NYP/Weill Cornell Medical Center
New York, New York, 10065, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.